Novel technology under development by CPSI offers great potential in the battle against pancreatic cancer 

OWEGO, NY – A story focusing on CPSI’s novel anti-cancer device platform recently aired on FOX40 WICZ-TV Binghamton. The segment featured CPSI’s FrostBite cryoablation technology which is designed to use freezing to target and destroy pancreatic cancer tumors. The FrostBite technology represents the first endoscopic ultrasound compatible trans-esophageal cryoablation device of its kind. The team at CPSI has developed the prototype catheter and conducted a series of pilot pre-clinical studies in conjunction with collaborators at John Hopkins Medical School.

Speaking about the technology, Dr. John Baust (President of CPSI) stated, “As pancreatic cancer is a highly lethal disease with limited treatment options available to patients, we are looking forward to taking the next steps in development in support of moving FrostBite closer to commercialization. While FrostBite is still in the R&D phase, the technology results look very promising and we hope to be able to move through the final development and testing necessary for FDA approval and commercialization.”

Click here to read the full press release: News Segment Features CPSI’s FrostBite Cancer Treatment Device

View the feature story on FOX 40 WICZ-TV Binghamton

View other CPSI Biotech news and recent patent announcements